se of paracetamol in resolving acute kidney injury in severe malaria

Phase 2

• Conditions: Preventing cell-free haemoglobin renal toxicity and ameliorating Acute Kidney Injury (AKI) in children with haemoglobinuric severe malaria; Infections and Infestations; Plasmodium falciparum malaria

• Registration Number: ISRCTN84974248
• Lead Sponsor: European & Developing Countries Clinical Trials Partnership

Brief Summary

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37524553/ (added 01/08/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-08
• Last Update Posted: 21 August 2023
• Study Completion: 2024-04-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Children aged >6 months to <12 years
2. Positive RDT for P. falciparum malaria at admission
3. One of the following features of severe malaria confirmed haemoglobinuria, impaired consciousness and/or severe respiratory distress
4. Guardian or parent willing and able to provide consent

Exclusion Criteria

1. Surgery
2. Acute trauma or burns
3. Known allergy to paracetamol
4. Impaired liver function tests
5. Known chronic renal failure or suspected non-malarial causes of renal impairment
6. Refusal to consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified